Search company, investor...


Founded Year



Acquired | Acquired

Total Raised


About AlgoNomics

AlgoNomicsa€ premier product is the EpibaseA platform for T-cell epitope identification in different population groups,applied in the discovery of vaccines and therapeutic proteins

Headquarters Location

Technologiepark 4



Missing: AlgoNomics's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: AlgoNomics's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing AlgoNomics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

AlgoNomics is included in 1 Expert Collection, including Regenerative Medicine.


Regenerative Medicine

1,818 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).

AlgoNomics Patents

AlgoNomics has filed 1 patent.

patents chart

Application Date

Grant Date


Related Topics




Immune system, Immunology, Clusters of differentiation, Transcription factors, Proteins


Application Date


Grant Date



Related Topics

Immune system, Immunology, Clusters of differentiation, Transcription factors, Proteins



Latest AlgoNomics News

Lonza buys into immunogenicity

Jul 29, 2013

By Nick TaylorNick Taylor , 05-Nov-20092009-11-05T00:00:00Z Related tags: Algonomics, Lonza, Immunogenicity Lonza has bolstered its protein design capabilities by acquiring Algonomics, a CRO with technologies which predict immunogenicity to improve development of protein therapeutics and vaccines. Immunogenicity can pose a significant obstacle in the development of biologics and identifying candidates that may have safety issues allows companies to filter out these drugs, which is especially important given the high costs of failure. Lonza has expressed a desire to expand its service offering through acquisitions, having withdrawn its bid for Patheon, and has begun this process by acquiring the immunogenicity focused contract research organisation (CRO). The acquisition gives Lonza access to Algonomics’ Epibase and Epibase IV platforms which provide in silico T-cell epitope screening and in vitro T-cell assays respectively. By using these technologies drug candidates can quickly, accurately and cost-effectively be screened. Using this data companies can rank proteins or vaccines, develop a risk management plan and boost immune responses. Lonza plans to use the technologies in conjunction with its existing AggreSolve technology, which can predict a protein’s stability and the likelihood it will aggregate. This will provide “a comprehensive solution is offered for the design and optimization of biologics”, according to Philippe Stas, CEO of Algonomics. Algonomics technology portfolio also includes a protein modelling platform, called Tripole, which can build 3-D structures by homology, search for structural similarities between proteins and compute surface and packaging interactions. Tripole can be used in conjunction with Epibase to eliminate potential epitopes on the protein while maintaining its functionality. Lonza acquired all the shares of Algonomics for an undisclosed fee. The companies have now begun integrating Algonomics’ technologies and staff into Lonza’s operations. Stas will join Lonza and continue to run Algonomics. This content is copyright protected However, if you would like to share the information in this article, you may use the headline, summary and link below: Lonza buys into immunogenicity By Nick TaylorNick Taylor, 05-Nov-2009 Lonza has bolstered its protein design capabilities by acquiring Algonomics, a CRO with technologies which predict immunogenicity to improve development of protein therapeutics and vaccines. Copyright - Unless otherwise stated all contents of this web site are © 2015 - William Reed Business Media SAS - All Rights Reserved - Full details for the use of materials on this site can be found in the Terms & Conditions Related news:

AlgoNomics Frequently Asked Questions (FAQ)

  • When was AlgoNomics founded?

    AlgoNomics was founded in 1999.

  • What is AlgoNomics's latest funding round?

    AlgoNomics's latest funding round is Acquired.

  • How much did AlgoNomics raise?

    AlgoNomics raised a total of $2M.

  • Who are the investors of AlgoNomics?

    Investors of AlgoNomics include Lonza Group, Gemma Frisius Fonds, TrustCapital Partners and Baekeland Fund.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.